ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

PreOmics Introduces a Novel BeatBox™ FFPE Workflow for Accelerated, In-depth Tissue Proteomics

  • Introduction of a FFPE workflow extends the tissue proteomics applications of PreOmics’ unique BeatBox™ technology
  • Launch of novel FFPE workflow enables high-throughput, robust and fast processing of tissue samples
  • Bruker and PreOmics to co-commercialize BeatBox workflows

At the AACR Annual Meeting 2023, PreOmics GmbH announced the launch of a BeatBox-based FFPE workflow, which simplifies, speeds up and standardizes FFPE sample preparation for deep, unbiased tissue proteomics by subsequent protein digestion and nanoLC-MS/MS analysis. The novel BeatBox workflow eliminates the need for xylene-based deparaffinization and enables fast and robust processing of up to 96 samples in parallel for discovery research, as well as for reproducible larger cohort translational and preclinical research and validation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230414005064/en/

BeatBox is a dedicated system for convenient, semi-automated sample homogenization of many tissue types and cells (Photo: Business Wire)

BeatBox is a dedicated system for convenient, semi-automated sample homogenization of many tissue types and cells (Photo: Business Wire)

The BeatBox™ tissue homogenizer and cell lyser is a compact, affordable and stand-alone benchtop system for convenient, semi-automated sample homogenization of various tissue types and cells. With flexible input amounts from 1-50 mg, it consistently delivers reproducible results for LC-MS-based proteomics with scalable throughput from 1-96 samples. Already successful for fresh tissue and cell-line proteomics, with the novel FFPE protocol the BeatBox can now efficiently process FFPE samples for downstream tissue proteomics. Compared to sonication devices, the BeatBox requires no complex handling or additional water conditioning. FFPE or fresh frozen tissue homogenization takes just 10 minutes with push-button operation.

In a benchmark study, FFPE as well as fresh frozen mouse cardiac muscle, kidney, and liver tissue (provided by the Research Institute of Molecular Pathology in Vienna and the Histology Facility at Vienna BioCenter Core Facilities) was processed using the novel BeatBox FFPE workflow, as well as with a sonication approach. Peptides were analyzed on a timsTOF-HT mass spectrometer (Bruker Daltonics) in DIA-PASEF mode using a 30-minute nLC gradient. The BeatBox-based FFPE workflow was shown to increase the proteomic depth for FFPE, as well as for fresh frozen tissue on average by 14% to 43%, depending on tissue type. Typical Coefficients of Variation (CV) within replicates were below 10%, emphasizing the high repeatability of the homogenization process with the compact BeatBox instrument. Furthermore, the novel approach saves up to 4 hours of time in comparison to the sonication workflow, enabling parallelized high-throughput processing of 96 samples within one working day.

Dr. Michael Wierer, Director of the Proteomics Research Infrastructure at the University of Copenhagen, states: “We routinely analyze a large number of tissue samples at once, and to improve our efficiency, we have successfully adapted the BeatBox technology for tissue homogenization. Our latest discovery is that the BeatBox technology can efficiently homogenize paraffin-embedded tissue scrolls. This breakthrough now allows us to process large cohorts of FFPE tissue quickly, reproducibly, and with greater precision, opening up the possibility of large-scale biobank projects. By leveraging this technology, we are excited to uncover novel deep proteomics insights in the field of pathology research.”

Dr. Marcello Stein, Chief Marketing Officer of PreOmics, commented: “With our novel BeatBox-based FFPE workflow, researchers finally can simplify, speed-up and standardize FFPE sample preparation without the need of xylene-based deparaffinization to fully exploit its potential for unbiased, deep proteomics. We believe this is a leap forward for the preparation and subsequent proteomic analysis of large sample cohorts.”

Bruker Corporation (Nasdaq: BRKR) and PreOmics have a commercial agreement, enabling Bruker to offer the BeatBox-based tissue workflows for sale with Bruker's timsTOF Pro mass spectrometer.

Have a look yourself: PreOmics representatives will be at the AACR Bruker booth #1818 to showcase the BeatBox and FFPE application note. The application note can be accessed at https://www.preomics.com/applications/ffpe.

About PreOmics GmbH

PreOmics empowers our clients in life sciences to establish biological knowledge through efficient, reliable solutions and workflows that set the standard for protein analysis. Our team spirit, energy, and commitment empower us to be both creative and quality focused – A trusted partner with deeply rooted scientific experience. We envisage a future with revolutionary proteomic discovery processes open for everyone. Tools that reveal hidden causes of diseases, ensure sustainable nutrition, and provide diagnoses that enhance lives and society.

Website: www.preomics.com

Address: Am Klopferspitz 19 | 82152 Planegg/Martinsried | Germany

Contacts

Dr. Garwin Pichler

Founder & Managing Director

PreOmics GmbH

Email: info@preomics.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.